Document Detail

Can magnesium sulfate reduce the risk of cerebral injury after perinatal asphyxia?
MedLine Citation:
PMID:  10715892     Owner:  NLM     Status:  MEDLINE    
Hypoxia-ischemia produces brain damage by processes that continue for many hours after reoxygenation/reperfusion. This provides a window of opportunity for therapy aimed at preventing further loss of brain cells. Sulfate magnesium can prevent posthypoxic brain injury by blocking glutamate receptors within the calcium (Ca++) ion channel. We used sulfate magnesium in nine newborn infant after perinatal hypoxia. We investigated the brain damage, by ultrasound examination, on third day, in first, second and third week, and third, sixth month of life. We have estimated the neurological development in the first week of life and third and twelfth month of life. We did not find deviations in ultrasound examination. We did not observe convulsions. We did not observe any side effect of this therapy. The examination at 1 of year of life in all of children was correct.
I Maroszyńska; B Sobolewska; E Gulczyńska; L Zylińska; E Lerch; M Kicińska; M Rudecka
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta poloniae pharmaceutica     Volume:  56     ISSN:  0001-6837     ISO Abbreviation:  Acta Pol Pharm     Publication Date:    1999 Nov-Dec
Date Detail:
Created Date:  2000-04-27     Completed Date:  2000-04-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985167R     Medline TA:  Acta Pol Pharm     Country:  POLAND    
Other Details:
Languages:  eng     Pagination:  469-73     Citation Subset:  IM    
Polish Mother's Health Center, Department of Neonatology, Lódź, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Asphyxia Neonatorum / complications,  drug therapy*,  pathology
Brain / pathology*
Cell Death / drug effects
Cerebrovascular Circulation / drug effects
Infant, Newborn
Magnesium Sulfate / adverse effects,  therapeutic use*
Reg. No./Substance:
7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparative study of antithrombotic and antiaggregatory activity of acetylsalicylic acid, ticlopidin...
Next Document:  Australian teledermatology: the patient, the doctor and their government.